WASHINGTON (dpa-AFX) - (Adds outlook)

For the full year, IDEXX Laboratories, Inc. (IDXX) has revised down its annual
outlook.

The company now expects net income per share of $10.82 to $11.20 against
previous outlook of $10.84 to $11.33 per share, citing around $0.11 negative
foreign exchange rate impact.

Analysts, on average, expect the company to post income per share of $11.12, for
the year.

Revenue is projected to be in the range of $3.895 billion to $3.965 billion
versus its earlier view of $3.930 billion to $4.04 billion. The Street estimate
stands at $3.99 billion.

This new revenue outlook includes a $35 million negative impact from the recent
strengthening of the dollar and a reduction of 1 percent to the high end of the
organic revenue growth range to reflect near-term moderation in the U.S.
clinical visit growth trends.

Q1 Results:

IDEXX reported a profit for its first quarter that increased from the same
period last year and beat the Street estimates.

The company's bottom line totaled $235.58 million, or $2.81 per share. This
compares with $214.05 million, or $2.55 per share, in last year's first quarter.

Analysts on average had expected the company to earn $2.67 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 7.1% to $964.10 million from $900.20
million last year.

IDEXX Laboratories Inc earnings at a glance (GAAP) :

-Earnings (Q1): $235.58 Mln. vs. $214.05 Mln. last year.
-EPS (Q1): $2.81 vs. $2.55 last year.
-Revenue (Q1): $964.10 Mln vs. $900.20 Mln last year.

-Guidance:
Full year EPS guidance: $10.82 - $11.20
Full year revenue guidance: $3,895 - $3,965 Mln



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX